Michel Praet

2.7k total citations · 1 hit paper
20 papers, 1.9k citations indexed

About

Michel Praet is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Michel Praet has authored 20 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 5 papers in Pulmonary and Respiratory Medicine and 3 papers in Molecular Biology. Recurrent topics in Michel Praet's work include Colorectal Cancer Treatments and Studies (5 papers), Pancreatic and Hepatic Oncology Research (3 papers) and Museums and Cultural Heritage (3 papers). Michel Praet is often cited by papers focused on Colorectal Cancer Treatments and Studies (5 papers), Pancreatic and Hepatic Oncology Research (3 papers) and Museums and Cultural Heritage (3 papers). Michel Praet collaborates with scholars based in Belgium, France and Netherlands. Michel Praet's co-authors include Eric Van Cutsem, Laurence Collette, Ullrich Bethe, Bernard Nordlinger, Philippe Rougier, Daniel Jaeck, Werner Scheithauer, Rowan W. Parks, Halfdan Sørbye and John Primrose and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Annals of Oncology.

In The Last Decade

Michel Praet

16 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial

2008 1.4k citations Bernard Nordlinger, Halfdan Sørbye et al. The Lancet profile →

Peers

Countries citing papers authored by Michel Praet

Since Specialization

Citations

This map shows the geographic impact of Michel Praet's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michel Praet with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michel Praet more than expected).

Fields of papers citing papers by Michel Praet

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michel Praet. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michel Praet. The network helps show where Michel Praet may publish in the future.

Co-authorship network of co-authors of Michel Praet

This figure shows the co-authorship network connecting the top 25 collaborators of Michel Praet. A scholar is included among the top collaborators of Michel Praet based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michel Praet. Michel Praet is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	La restitution des restes humains présents dans les collections françaises 2021 ·La Lettre de l’OCIM ·Michel Praet	0
2	The Modernity of the Museum: Sharing and Creating Knowledge Through Confrontation with the Material Evidences of the Past and the Present 2019 ·Museum International ·Michel Praet	2
3	Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983) 2016 ·Bernard Nordlinger, Halfdan Sørbye, Bengt Glimelius, Graeme J. Poston, Peter M. Schlag, Philippe Rougier, Wolf O. Bechstein, John Primrose, Euan Walpole, Meg Finch-Jones, Daniel Jaeck, Darius Mirza, Rowan W. Parks, Laurence Collette, Michel Praet, Ullrich Bethe, Eric Van Cutsem, Werner Scheithauer, Thomas Gruenberger	0
4	Adjuvant Ganglioside GM2-KLH/QS-21 Vaccination Versus Observation After Resection of Primary Tumor > 1.5 mm in Patients With Stage II Melanoma: Results of the EORTC 18961 Randomized Phase III Trial 2013 ·Journal of Clinical Oncology ·Alexander M.M. Eggermont, Stefan Suciu, Piotr Rutkowski, Jeremy Marsden, Mario Santinami, Pippa Corrie, Steinar Aamdal, Paolo A. Ascierto, Poulam M. Patel, Wim H.J. Kruit, Lars Bastholt, Lorenzo Borgognoni, Maria Grazia Bernengo, Neville Davidson, (unknown), Michel Praet, Alan Spatz	76
5	O-0028 Adjuvant Folfox4 +/- Cetuximab in KRAS Wild-Type Patients with Resected Stage III Colon Cancer Results from the Petacc8 Intergroup Trial 2012 ·Annals of Oncology ·Julien Taı̈eb, Josep Tabernero, Enrico Mini, Fabien Subtil, Gunnar Folprecht, Jean‐Luc Van Laethem, Josef Thaler, John Bridgewater, (unknown), Lone Nørgård Pétersen, Philippe Rougier, Laurence Collette, Michel Praet, (unknown), Martina Schneider, Pierre Squifflet, Pierre Laurent‐Puig, Eric Van Cutsem, Laurent Bedenne, Côme Lepage	4
6	Adjuvant Gemcitabine Alone Versus Gemcitabine-Based Chemoradiotherapy After Curative Resection for Pancreatic Cancer: A Randomized EORTC-40013-22012/FFCD-9203/GERCOR Phase II Study 2010 ·Journal of Clinical Oncology ·Jean–Luc Van Laethem, Pascal Hammel, F. Mornex, D. Azria, Geertjan van Tienhoven, Philippe Vergauwe, Marc Peeters, Marc Polus, Michel Praet, Murielle Mauer, Laurence Collette, Volker Budach, Manfred P. Lutz, Eric Van Cutsem, Karin Haustermans	189
7	Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial breakdown → 2008 ·The Lancet ·Bernard Nordlinger, Halfdan Sørbye, Bengt Glimelius, Graeme J. Poston, Peter M. Schlag, Philippe Rougier, Wolf O. Bechstein, John Primrose, Euan Walpole, Meg Finch-Jones, Daniel Jaeck, Darius Mirza, Rowan W. Parks, Laurence Collette, Michel Praet, Ullrich Bethe, Eric Van Cutsem, Werner Scheithauer, Thomas Gruenberger	1396
8	Raltitrexed (Tomudex®) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1) 2008 ·European Journal of Cancer ·I Popov, Alfredo Carrato, Alberto Sobrero, Mark Vincent, David Kerr, Roberto Labianca, Angelo Raffaele Bianco, Mostafa El-Serafi, Laurent Bedenne, B Paillot, Enrico Mini, (unknown), John J. Welch, Laurence Collette, Michel Praet, J. Wils	37
9	Weekly Infusional High-Dose Fluorouracil (HD-FU), HD-FU Plus Folinic Acid (HD-FU/FA), or HD-FU/FA Plus Biweekly Cisplatin in Advanced Gastric Cancer: Randomized Phase II Trial 40953 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group and the Arbeitsgemeinschaft Internistische Onkologie 2007 ·Journal of Clinical Oncology ·Manfred P. Lutz, H. Wilke, D. J. Theo Wagener, U. Vanhoefer, Krzysztof Jeziorski, Susanna Hegewisch‐Becker, Leopold Balleisen, (unknown), Slinger Jansen, Muriel Debois, Ullrich Bethe, Michel Praet, J. Wils, Eric Van Cutsem	46
10	Docetaxel Plus Gemcitabine or Docetaxel Plus Cisplatin in Advanced Pancreatic Carcinoma: Randomized Phase II Study 40984 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group 2005 ·Journal of Clinical Oncology ·Manfred P. Lutz, Eric Van Cutsem, (unknown), Jean–Luc Van Laethem, U. Vanhoefer, J. Wils, (unknown), (unknown), Jean Arnaud, Emmanuel Mitry, (unknown), Peter Reichardt, (unknown), Pierre-Luc Etienne, Thomas Lingenfelser, Michel Praet, B. Genicot, Muriel Debois, Bernard Nordlinger, Michel Ducreux	40
11	Heritage and Scientific Culture: the intangible in science museums in France 2004 ·Museum International ·Michel Praet	6
12	Patrimoines et identités 2002 ·Joëlle Le Marec, Jean Davallon, (unknown), Michel Praet, (unknown), (unknown), (unknown), Yves Bergeron	0
13	La muséologie des sciences et ses publics : regards croisés sur la Grande Galerie de l'Évolution du Muséum national d'histoire naturelle 2000 ·Presses Universitaires de France eBooks ·(unknown), Michel Praet	3
14	L’esprit du lieu, un concept muséologique 2000 ·Cairn.info ·Michel Praet, (unknown), (unknown)	0
15	Cellular uptake, cytotoxicity, and transport kinetics of anthracyclines in human sensitive and multidrug-resistant K562 cells 1996 ·Biochemical Pharmacology ·Michel Praet, Pierre Stryckmans, Jean‐Marie Ruysschaert	20
16	In-vivo and in-vitro mitochondrial membrane damages induced in mice by adriamycin and derivatives 1993 ·Biochimica et Biophysica Acta (BBA) - Biomembranes ·Michel Praet, Jean‐Marie Ruysschaert	31
17	Increasing therapeutic effect and reducing toxicity of doxorubicin by N-acyl dehydroalanines 1989 ·European Journal of Cancer and Clinical Oncology ·Pedro Buc Calderón, Michel Praet, Jean Marie Ruysschaert, Marcel Roberfroid	13
18	Detection of lytic antimycobacterial antibodies by immune lysis of liposomes sensitized to tuberculin 1988 ·Journal of Immunological Methods ·F. Legros, M. Castillo, Michel Praet, Michel Vandenbranden, (unknown), Véronique Cabiaux, Jean‐Paul Van Vooren, (unknown), Paul Dierckx, M. Turneer, Jean‐Marie Ruysschaert	1
19	Amylase and trypsin- and chymotrypsin-like proteases from Actinia equina L.; Their role in the nutrition of this sea anemone 1982 ·Comparative Biochemistry and Physiology Part A Physiology ·Michel Praet	19
20	Les types de polypes d'Hydraires conservés au Muséum national d'Histoire naturelle de Paris 1979 ·Michel Praet	11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact